• OncoImmune receives FDA approval for COVID-19 clinical trial pharmaceutical-business-review
    April 14, 2020
    OncoImmune has received a study-may-proceed letter from the FDA for its Phase III clinical trial testing the safety and efficacy of CD24Fc for the treatment of hospitalized COVID-19 patients (SAC-COVID).
PharmaSources Customer Service